Preclinical and clinical evidence indicates that anti-VEGF (vascular endothelial growth factor) therapy creates a transient window of vessel normalization which improves tumour oxygenation and the delivery of therapeutic agents [15, 49]. Here, VEGFA is linked to neoplasm.